Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) Purified Anti-human IFN-gamma Antibody     Product Data Sheet (PDF)    
Purified Anti-human IFN-γ Antibody
3112505 50 µg $75.00       
3112510 500 µg $195.00       
Clone: 4S.B3
Isotype: Mouse IgG1, κ
Reactivity: Human, Cross-Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus
Immunogen: Partially purified, native human IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application:

ELISA - Quality tested
WB - Validated
ICFC - Reported in the literature

Application Notes:

ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody or purified MD-1 antibody as the capture antibody.
Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.
Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.

Recommended Usage:

Each lot of this antibody is quality control tested by ELISA assay. For ELISA Capture applications, the antibody should be titrated between 0.25 - 2 µg/ml to determine optimal condition. For Western blotting, the suggested use of this reagent is 0.5 - 2.0 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Application References:

1. Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut)
2. Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut)
3. Sester M, et al. 2002. J. Virol. 76:3748. (ICFC)
4. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC)
5. Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA)
6. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
7. Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC)
8. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)

PMA/Ionomycin-stimulated human PBMCs were stained

PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cy5 and 4S.B3 PE.

Western blot analysis of 50

Western blot analysis of 50 ng recombinant human IFN-γ (lane 1), recombinant rat IFN-γ (lane 2), and recombinant mouse IFN-γ (lane 3) using anti-human IFN-γ (clone 4S.B3) antibody followed by HRP anti-mouse IgG secondary antibody.



Description:

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Structure: Cytokine; dimer; 20-25 kD (Mammalian)
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Cellular Sources: CD8+ and CD4+ T cells, NK cells
Cellular Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Bioactivity/Activities: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Antigen References:

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.